Skip to content

Efficacy study of spray containing Zanthoxylum rhetsa pericarp essential oil in primary knee osteoarthritis patients

Efficacy study of spray containing Zanthoxylum rhetsa pericarp essential oil in primary knee osteoarthritis patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230906004
Enrollment
60
Registered
2023-09-06
Start date
2022-04-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To study the effectiveness of ZR spray (test group, 30), comparison to Diclofenac spray (standard control group, 30) in primary osteoarthritis of knee patients. On second follow up, after day 14, participants in control group (1) and test group (1) were dropout due to infect the Coronavirus disease (COVID-19). Zanthoxylum rhetsa, Osteoarthritis, VAS, WOMAC, Pain

Interventions

Spraying diclofenac spray on knee pain for 14 days (day 1 to day 14) and stopped spraying on day 15.,Spraying ZR spray on knee pain for 14 days (day 1 to day 14) and stopped spraying on day 15.
Active Comparator Drug,Experimental Drug
Diclofenac spray,ZR spray

Sponsors

Mae Fah Luang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Male and female between 45 to 85 years of age. 2. One side of knee pain more than 3 months, pain score from 3 to 10 assessed by 0 to 10 visual analog score (VAS). 4. Joint stiffness and crepitation sound. 5. Diagnosed with primary OA knee by Orthopedics doctor with based on the American College of Rheumatology 's clinical and radiographic finding and classified to 1 to 4 grading based on Kellgren and Lawrence radiographic. 6. Treated by only intake acetaminophen or NSAIDs or muscle relaxant or sysadoa.

Exclusion criteria

Exclusion criteria: 1. Body mass index (BMI) over 32 kg/m2. 2. Participants with hypersensitivity on essential oil or perfume. 3. Participants in among pregnancy, breastfeeding, cancer, infectious diseases, and disability. 4. Participants who undergoing alternative treatment with massage, acupuncture, etc or physical therapy. 5. Participants who were treated by intake or inject corticosteroids prior research 3 months, or treated by hyaluronic injection prior research 6 months.

Design outcomes

Primary

MeasureTime frame
Pain score day 0, after day 7, after day 14 Independent t-test, Mann-Whitney U test, Paired Samples t-test, or Wilcoxon Signed Ranks test

Secondary

MeasureTime frame
WOMAC index score day 0, after day 7, after day 14 Independent t-test, Mann-Whitney U test, Paired Samples t-test, or Wilcoxon Signed Ranks test

Countries

Thailand

Contacts

Public ContactChureeporn Imphat

School of Integrative Medicine, Mae Fah Luang University

chureeporn.imp@mfu.ac.th0884351461

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026